
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty Corp is projected to experience significant revenue growth, with a forecasted increase of over 20% annually through 2026, driven by the commercial success of products like Vabysmo, Ojemda, and Miplyffa. In 2024, XOMA reported total income and revenues from royalty agreements of $28.5 million, a substantial rise from $4.8 million in the previous year, highlighting the effectiveness of both acquisitions and internal growth strategies. Looking forward, the company anticipates generating $49.0 million in revenues for 2026, a notable 36% increase over 2025, supported by both existing commercial-stage assets and potential milestone payments from earlier-stage assets assuming positive clinical progress.
Bears say
XOMA Royalty Corp has experienced revenue and net earnings variability attributed to its operations in the fluctuating international market, which is susceptible to economic downturns, new tariffs, and changes in governmental reimbursement policies. The company’s reliance on external partnerships for future economic rights poses significant risks, as any adverse developments, including failed clinical trials or funding challenges, could impede its drug development pipeline and overall operational stability. Furthermore, recent declines in the company's stock performance following pandemic-related highs highlight the volatility inherent in the biotechnology sector, exacerbated by potential leadership turnover that may compromise institutional knowledge and strategic direction.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares